TPP Global Development is an innovative drug development company operating in the preclinical area of the drug discovery process. Its therapeutic focus areas are nervous system disorders, immunology/inflammation and niche oncology. The company sources early-stage pre-clinical drug programmes mainly from research institutes and universities. It develops programmes in the inventor's lab where possible or at local contract research organizations (CROs). Once programmes reach later stages of pre-clinical development, TPP aims to license them to Pharma or, when commercially sensible, establish them as separate spin-out companies. TPP has assembled an experienced board including CEO Tom Brown, CFO Peter Trill, Professor Michael Walker and Dr Sharon O’Kane, and recently raised capital to execute its development strategy.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

May 2010